

Corrigendum

**Corrigendum to “Bridged bicyclic vasopressin receptor antagonists with V<sub>2</sub>-selective or dual V<sub>1a</sub>/V<sub>2</sub> activity”**  
[Bioorg. Med. Chem. Lett. 12 (2002) 3081]<sup>☆</sup>

Alexey B. Dyatkin,<sup>a,\*</sup> William J. Hoekstra,<sup>a</sup> Dennis J. Hlasta,<sup>a</sup> Patricia Andrade-Gordon,<sup>a</sup>  
Lawrence de Garavilla,<sup>a</sup> Keith T. Demarest,<sup>b</sup> Joseph W. Gunnet,<sup>b</sup> William Hageman,<sup>a</sup>  
Richard Look<sup>b</sup> and Bruce E. Maryanoff<sup>a,\*</sup>

<sup>a</sup>*Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477-0776, USA*

<sup>b</sup>*Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ 08869-0602, USA*

The authors regret that compound numbers **4** and **5** were inadvertently interchanged in parts of this paper.

Line 3 of the Abstract should read: ‘... resulted in potent V<sub>2</sub>-selective (e.g., **5**) and ...’

Page 3081, column 2, lines 13–15 should read: ‘... as exemplified by derivative **5** and **10**. Compound **5**, with the *R* absolute configuration, shows...’

Page 3082, column 2, line 9–10 should read: ‘In contrast, **5** (the *R*-enantiomer of **4**) was V<sub>2</sub>-selective’.

Page 3084, column 2, line 2 should read: ‘... resulted in V<sub>2</sub>-selective (e.g., **5**) and ...’

<sup>☆</sup> DOI of original article: 10.1016/S0960-894X(02)00649-2

\* Corresponding authors. Tel.: +1-215-628-5008 (A.B.D.); tel.: +1-215-628-5530; fax: +1-215-628-4985 (B.E.M.); e-mail addresses: [adyatkin@prdus.ini.com](mailto:adyatkin@prdus.ini.com); [bmaryano@prdus.jnj.com](mailto:bmaryano@prdus.jnj.com)